Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02141282 |
Title | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy |
Recruitment | Completed |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | AbbVie |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |